Highlights
Abstract
Research Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor Tanihara and colleagues studied the short-term results of topically administered selective Rho kinase inhibitor, K-115, in a randomized, double-masked, placebo-controlled clinical trial. Fifty healthy volunteers received a single instillation, while another 50 healthy volunteers received repeated instillation of increasing concentrations in a stepwise manner. Maximal intraocular pressure reductions were noted 1 to 2 hours...